Efficacy and Safety of Mirabegron as Medical Expulsive Therapy for Distal Ureteral Stones

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035203

Enrollment

Unknown

Registered

2020-08-03

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal Ureteral Stones

Interventions

Mirabegron group:take mirabegron

Tamsulosin group:take Tamsulosin 0.4 mg once daily

Mirabegron+Tamsulosin:take Tamsulosin 0.4 mg +mirabegron 50mg once daily

Control group:take placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years; 2. Ureteral calculi (< 10mm) were diagnosed in patients with urological b-ultrasound, KUB or CT; 3. Stones can be shown in X film; 4. The patient's renal function is normal.

Exclusion criteria

Exclusion criteria: Bilateral ureteral calculi, severe hydronephrosis, severe urinary tract infection with symptoms, pregnancy and prior ureteral and bladder surgery, urinary system anatomical abnormalities or malformations, benign prostatic hyperplasia, isolated kidneys, use of calcium channel blockers or M receptor blockers.

Design outcomes

Primary

Measure	Time frame
Stone expulsion ratio;stone expulsion interval;total required analgesic dosage;	—

Countries

China

Contacts

Public ContactJianlin lv

The Affiliated Jiangning Hospital with Nanjing Medical University

ljjxx01@163.com+86 13770631917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026